Skip to main content
. 2022 Dec 1;17(12):e0265212. doi: 10.1371/journal.pone.0265212

Table 2. VISORB study outcomes [25].

Clinical Response (PE measurement) # of subjects (%)
34 (100)
    Complete Response 19 (56)
    Partial Response 10 (29)
    Stable Disease 2 (6)
    Progressive Disease 0 (0)
    Not Evaluable 3 (9)
Histological Response 27 (100)
    No sign of disease 18 (67)
    Disease present (clear margins) 6 (22)
    Disease present (extending to margins) 3 (11)